Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies

Rituximab (R) is increasingly incorporated in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in patients with B-cell malignancies, not only to improve disease control, but also to prevent graft-versus-host disease (GVHD). There are no random...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Main Authors: Tomaszewska, Agnieszka, Jagasia, Madan, Beohou, Eric, van der Werf, Steffie, Blaise, Didier, Kanfer, Edward, Milpied, Noel, Reményi, Péter, Ciceri, Fabio, Bourhis, Jean H., Chevallier, Patrice, Solano, Carlos, Socié, Gerard, Bruno, Benedetto, Rambaldi, Alessandro, Castagna, Luca, Kröger, Nicolaus, Corradini, Paolo, Afanasyev, Boris, Ladetto, Marco, Niederwieser, Dietger, Scheid, Christof, Sengeloev, Henrik, Kroschinsky, Frank, Yakoub-Agha, Ibrahim, Schoemans, Helene, Koenecke, Christian, Penack, Olaf, Perić, Zinaida, Greinix, Hildegard, Duarte, Rafael F., Basak, Grzegorz W.
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7884746/
https://ncbi.nlm.nih.gov/pubmed/33603743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.613954
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares